

A randomised controlled trial to study the side effect profile and to establish measures of efficacy using photofrin or 5-aminolaevulinic acid (ALA) photodynamic therapy in the eradication of dysplasia in Barretts columnar lined oesophagus

| | | |
|--|--|--|
| Submission date 26/01/2006 | Recruitment status No longer recruiting | <input type="checkbox"/> Prospectively registered |
| Registration date 07/02/2006 | Overall study status Completed | <input type="checkbox"/> Protocol |
| Last Edited 28/08/2013 | Condition category Nutritional, Metabolic, Endocrine | <input type="checkbox"/> Statistical analysis plan |
| | | <input checked="" type="checkbox"/> Results |
| | | <input type="checkbox"/> Individual participant data |

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Laurence Lovat

Contact details

National Medical Laser Centre
Charles Bell House
67-73 Riding House Street
London
United Kingdom
W1W 7EJ
med.laser@ucl.ac.uk

Additional identifiers

Protocol serial number

Version 3.1

Study information

Scientific Title

Study objectives

To determine whether photodynamic therapy for high grade dysplasia in Barrett's oesophagus using aminolaevulinic acid has less side effects than photofrin. To develop novel measures of efficacy.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Berkshire Research Ethics Committee, 13/01/2006, ref: 05/Q1602/193

Study design

Randomised controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

High grade dysplasia in Barrett's oesophagus

Interventions

Photodynamic therapy using 5-aminolaevulinic acid versus photofrin

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Aminolaevulinic Photofrin

Primary outcome(s)

1. Eradication of high grade dysplasia
2. Prevention of oesophageal cancer
3. Side effect profiles of different types of photodynamic therapy

Key secondary outcome(s))

1. Quality of life outcomes
2. Develop novel methods for treatment efficacy
3. Reversal of Barrett's oesophagus

Completion date

01/02/2009

Eligibility

Key inclusion criteria

1. Patients with high grade dysplasia in Barrett's oesophagus but without invasive cancer
2. Aged over 21

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

1. Severe cardiovascular disease
2. Liver cirrhosis or seriously impaired hepatic or renal function
3. Depot antipsychotics
4. Concomitant chemoradiotherapy
5. Pregnancy
6. Porphyria
7. Previous photodynamic therapy

Date of first enrolment

01/02/2006

Date of final enrolment

01/02/2009

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

National Medical Laser Centre

London

United Kingdom

W1W 7EJ

Sponsor information

Organisation

University College London (UK)

ROR

<https://ror.org/02jx3x895>

Funder(s)

Funder type

Government

Funder Name

National Medical Laser Centre (UK)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---------------------------------|---------|--------------|------------|----------------|-----------------|
| Results article | results | 01/05/2013 | | Yes | No |